Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia

Leukemia and Lymphoma

Volumn 47, Issue 5, 2006, Pages 815-825

  Chim, Chor Sang ^a   Kwong, Yok Lam ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

APL; CDKN2B; Methylation; Prognostic factor

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; APC PROTEIN; ARSENIC TRIOXIDE; AZACITIDINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; METHYL CPG BINDING PROTEIN 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P15; PROTEIN P53; RETINOIC ACID; UNCLASSIFIED DRUG; UVOMORULIN;

ACUTE LEUKEMIA; ALGORITHM; CELL CYCLE ARREST; CHROMATIN; CPG ISLAND; DISEASE FREE INTERVAL; DNA METHYLATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SILENCING; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; LEUKOCYTE COUNT; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN METHYLATION; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROGNOSIS; PROMOTER REGIONS (GENETICS); RISK ASSESSMENT;

EID: 33744920104     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500513827     Document Type: Review

References (71)

1. Lo Coco, F and Nervi, C and Avvisati, G and Mandelli, F. (1998) Acute promyelocytic leukemia: A curable disease Leukemia, 12, pp. 1866-1880.
2. Chim, C and Liang, R and Kwong, Y and Lie, A and Todd, D and Chan, T. (1999) Treatment of de novo acute myeloid leukaemia in Hong Kong: A twenty-year experience Australia & New Zealand Journal of Medicine, 29, pp. 726-730.
3. De The, H and Chomienne, C and Lanotte, M and Degos, L and Dejean, A. (1990) The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus Nature, 347, pp. 558-561.
4. Kakizuka, A and Miller, W, Jr and Umesono, K and Warrell, R, Jr and Frankel, S and Murty, V and (1991) Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML Cell, 66, pp. 663-674.
5. Fenaux, P and Chomienne, C and Degos, L. (2001) All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia Seminars in Hematology, 38, pp. 13-25.
6. Head, D and Kopecky, K and Weick, J and Files, J and Ryan, D and Foucar, K and (1995) Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia Blood, 86, pp. 1717-1728.
7. Estey, E. (1997) Prognostic factors in clinical cancer trials Clinical Cancer Research, 3, pp. 2591-2593.
8. Kantarjian, H and Keating, M and Walters, R and Estey, E and McCredie, K and Smith, T and (1986) Acute promyelocytic leukemia. M.D. Anderson Hospital experience American Journal of Medicine, 80, pp. 789-797.
9. Rodeghiero, F and Avvisati, G and Castaman, G and Barbui, T and Mandelli, F. (2000) Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients Blood, 75, pp. 2112-2117.
10. Huang, M and Ye, Y and Chen, S and Chai, J and Lu, J and Zhoa, L and (1988) Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia Blood, 72, pp. 567-572.
11. Chim, C and Kwong, Y and Liang, R and Chu, Y and Chan, C and Chan, L and (1996) All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL) Hematology & Oncology, 14, pp. 147-154.
12. Degos, L and Dombret, H and Chomienne, C and Daniel, M and Miclea, J and Chastang, C and (1995) All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia Blood, 85, pp. 2643-2653.
13. Fenaux, P and Le Deley, M and Castaigne, S and Archimbaud, E and Chomienne, C and Link, H and (1993) Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group Blood, 82, pp. 3241-3249.
14. Fenaux, P and Chastang, C and Chevret, S and Sanz, M and Dombret, H and Archimbaud, E and (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group Blood, 94, pp. 1192-1200.
15. Tallman, M and Andersen, J and Schiffer, C and Appelbaum, F and Feusner, J and Woods, W and (2002) All-trans retinoic acid in acute promyelocytic leukemia: Long-term outcome and prognostic factor analysis from the North American Intergroup protocol Blood, 100, pp. 4298-4302.
16. Tallman, M and Andersen, J and Schiffer, C and Appelbaum, F and Feusner, J and Ogden, A and (1997) All-trans-retinoic acid in acute promyelocytic leukemia New England Journal of Medicine, 337, pp. 1021-1028.
17. Latagliata, R and Petti, M and Fenu, S and Mancini, M and Spiriti, M and Breccia, M and (2002) Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: An emerging problem Blood, 99, pp. 822-824.
18. Au, W and Lie, A and Chim, C and Liang, R and Ma, S and Chan, C and (2003) Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia Annals of Oncology, 14, pp. 752-757.
19. De Botton, S and Chevret, S and Sanz, M and Dombret, H and Thomas, X and Guerci, A and (2001) Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial British Journal of Haematology, 111, pp. 801-806.
20. Lin, P and Hao, S and Medeiros, L and Estey, E and Pierce, S and Wang, X and (2004) Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis American Journal of Clinical Pathology, 121, pp. 402-407.
21. Fenaux, P and Chevret, S and Guerci, A and Fegueux, N and Dombret, H and Thomas, X and (2000) Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group Leukemia, 14, pp. 1371-1377.
22. Burnett, A and Grimwade, D and Solomon, E and Wheatley, K and Goldstone, A. (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial Blood, 93, pp. 4131-4143.
23. Sanz, M and Lo Coco, F and Martin, G and Avvisati, G and Rayon, C and Barbui, T and (2000) Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups Blood, 96, pp. 1247-1253.
24. Asou, N and Adachi, K and Tamura, J and Kanamaru, A and Kageyama, S and Hiraoka, A and (1998) Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group Journal of Clinical Oncology, 16, pp. 78-85.
25. Asou, N and Adachi, K and Tamura, U and Kanamaru, A and Kageyama, S and Hiraoka, A and (2001) Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: The APL92 study of the Japan Adult Leukemia Study Group (JALSG) Cancer, Chemotherapy & Pharmacology, 48(Suppl 1), pp. S65-S71.
26. Murray, C and Estey, E and Paietta, E and Howard, R and Edenfield, W and Pierce, S and (1999) CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome? Journal of Clinical Oncology, 17, pp. 293-297.
27. Ferrara, F and Morabito, F and Martino, B and Specchia, G and Liso, V and Nobile, F and (2000) CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy Journal of Clinical Oncology, 18, pp. 1295-1300.
28. Lo Coco, F and Diverio, D and Falini, B and Biondi, A and Nervi, C and Pelicci, P. (1999) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia Blood, 94, pp. 12-22.
29. Herman, J and Baylin, S. (2003) Gene silencing in cancer in association with promoter hypermethylation New England Journal of Medicine, 349, pp. 2042-2054.
30. Chim, C and Liang, R and Kwong, Y. (2002) Gene promoter hypermethylation in hematologic malignancies Hematology & Oncology, 20, pp. 167-176.
31. Bird, A. (1992) The essentials of DNA methylation Cell, 70, pp. 5-8.
32. Costello, J and Fruhwald, M and Smiraglia, D and Rush, L and Robertson, G and Gao, X and (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns Natural Genetics, 24, pp. 132-138.
33. Esteller, M and Corn, P and Baylin, S and Herman, J. (2001) A gene hypermethylation profile of human cancer Cancer Research, 61, pp. 3225-3229.
34. Weinberg, R. (1991) Tumor suppressor genes Science, 254, pp. 1138-1146.
35. Knudson, A. (1997) Karnofsky Memorial Lecture. Hereditary cancer: Theme and variations Journal of Clinical Oncology, 15, pp. 3280-3287.
36. Drexler, H. (1998) Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells Leukemia, 12, pp. 845-859.
37. Siegfried, Z and Eden, S and Mendelsohn, M and Feng, X and Tsuberi, B and Cedar, H. (1999) DNA methylation represses transcription in vivo Natural Genetics, 22, pp. 203-206.
38. Roman-Gomez, J and Jimenez-Velasco, A and Agirre, X and Castillejo, J and Navarro, G and Barrios, M and (2004) Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia British Journal of Cancer, 91, pp. 707-713.
39. Roman, J and Castillejo, J and Jimenez, A and Bornstein, R and Gonzalez, M and del Carmen Rodriguez, M and (2001) Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome British Journal of Haematology, 113, pp. 329-338.
40. Roman-Gomez, J and Castillejo, J and Jimenez, A and Gonzalez, M and Moreno, F and Rodriguez Mdel, C and (2002) Torres A. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia Blood, 99, pp. 2291-2296.
41. Shen, L and Toyota, M and Kondo, Y and Obata, T and Daniel, S and Pierce, S and (2003) Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia Blood, 101, pp. 4131-4136.
42. Roman-Gomez, J and Jimenez-Velasco, A and Castillejo, J and Agirre, X and Barrios, M and Navarro, G and (2004) Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia Blood, 104, pp. 2492-2498.
43. Li, Q and Kopecky, K and Mohan, A and Willman, C and Appelbaum, F and Weick, J and Issa, J. (1999) Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia Clinical Cancer Research, 5, pp. 1077-1084.
44. Quesnel, B and Guillerm, G and Vereecque, R and Wattel, E and Preudhomme, C and Bauters, F and (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression Blood, 91, pp. 2985-2990.
45. Chim, C and Tam, C and Liang, R and Kwong, Y. (2001) Methylation of p15 and p16 genes in adult acute leukemia: Lack of prognostic significance Cancer, 91, pp. 2222-2229.
46. Kamb, A and Gruis, N and Weaver-Feldhaus, J and Liu, Q and Harshman, K and Tavtigian, S and (1994) A cell cycle regulator potentially involved in genesis of many tumor types Science, 264, pp. 436-440.
47. Nobori, T and Miura, K and Wu, D and Lois, A and Takabayashi, K and Carson, D. (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers Nature, 368, pp. 753-756.
48. Malumbres, M and Barbacid, M. (2001) To cycle or not to cycle: A critical decision in cancer Natural Cancer Reviews, 1, pp. 222-231.
49. Herman, J and Civin, C and Issa, J and Collector, M and Sharkis, S and Baylin, S. (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies Cancer Research, 57, pp. 837-841.
50. Chim, C and Liang, R and Tam, C and Kwong, Y. (2001) Methylation of p15 and p16 genes in acute promyelocytic leukemia: Potential diagnostic and prognostic significance Journal of Clinical Oncology, 19, pp. 2033-2040.
51. Sill, H and Aguiar, R and Schmidt, H and Hochhaus, A and Goldman, J and Cross, N. (1996) Mutational analysis of the p15 and p16 genes in acute leukaemias British Journal of Haematology, 92, pp. 681-683.
52. Chim, C and Fung, T and Liang, R. (2003) Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS Leukemia, 17, pp. 2533-2535.
53. Chim, C and Wong, S and Kwong, Y. (2003) Aberrant gene promoter methylation in acute promyelocytic leukaemia: Profile and prognostic significance British Journal of Haematology, 22, pp. 571-578.
54. Chim, C and Wong, S and Pang, A and Chu, P and Lau, J and Wong, K and Kwong, Y. (2005) Aberrant promoter methylation of the retinoic acid receptor alpha gene in acute promyelocytic leukemia Leukemia, 19, pp. 2241-2246.
55. Di Croce, L and Raker, V and Corsaro, M and Fazi, F and Fanelli, M and Faretta, M and (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor Science, 295, pp. 1079-1082.
56. Teofili, L and Martini, M and Luongo, M and Diverio, D and Capelli, G and Breccia, M and (2003) Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis Leukemia, 17, pp. 919-924.
57. Chim, C and Lau, J and Wong, K and Kwong, Y. (2005) CDKN2B methylation is an independent poor prognostic factor in newly diagnosed acute promyelocytic leukemia Leukemia. in press
58. Sanz, M and Martin, G and Gonzalez, M and Leon, A and Rayon, C and Rivas, C and (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group Blood, 103, pp. 1237-1243.
59. Vahdat, L and Maslak, P and Miller, W, Jr and Eardley, A and Heller, G and Scheinberg, D and Warrell, R, Jr. (1994) Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid Blood, 84, pp. 3843-3849.
60. Kiyoi, H and Naoe, T and Yokota, S and Nakao, M and Minami, S and Kuriyama, K and (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho) Leukemia, 11, pp. 1447-1452.
61. Noguera, N and Breccia, M and Divona, M and Diverio, D and Costa, V and De Santis, S and (2002) Alterations of the FLT3 gene in acute promyelocytic leukemia: Association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol Leukemia, 16, pp. 2185-2189.
62. Gilliland, D. (2003) FLT3-activating mutations in acute promyelocytic leukaemia: A rationale for risk-adapted therapy with FLT3 inhibitors Best Practice Research Clinics in Haematology, 16, pp. 409-417.
63. Callens, C and Chevret, S and Cayuela, J and Cassinat, B and Raffoux, E and de Botton, S and (2005) European APL Group. Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): A retrospective study from the European APL Group Leukemia, 19, pp. 1153-1160.
64. Au, W and Fung, A and Chim, C and Lie, A and Liang, R and Ma, E and (2004) FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological association ns and prognostic impact British Journal of Haematology, 125, pp. 463-469.
65. Issa, J and Kantarjian, H. (2005) Azacitidine Natural Reviews in Drug Discovery (Suppl), pp. S6-S7.
66. Lubbert, M and Minden, M. (2005) Decitabine in acute myeloid leukemia Seminars in Hematology, 42(2 Suppl 2), pp. S38-S42.
67. Au, W and Fung, A and Ma, E and Chan, C and Wong, K and Chim, C and (2005) Serial studies of methylation of CDKN2B and CDKN2A in relapsed acute promyelocytic leukaemia treated with arsenic trioxide British Journal of Haematology, 131, pp. 632-635.
68. Richardson, P and Barlogie, B and Berenson, J and Singhal, S and Jagannath, S and Irwin, D and (2005) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma Blood, 106, pp. 2977-2981.
69. He, L and Tolentino, T and Grayson, P and Zhong, S and Warrell, R, Jr and Rifkind, R and (2001) Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia Journal of Clinical Investigations, 108, pp. 1321-1330.
70. Cote, S and Rosenauer, A and Bianchini, A and Seiter, K and Vandewiele, J and Nervi, C and Miller, W, Jr. (2002) Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells Blood, 100, pp. 2586-2596.
71. Gale, R and Hills, R and Pizzey, A and Kottaridis, P and Swirsky, D and Gilkes, A and (2005) Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia Blood, 106, pp. 3768-3776.